Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 130
interventional 110
Observational 19
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 79
Drug|placebo 19
Drug|Other 3
Dietary Supplement|placebo 2
Drug|Procedure 2
Device|Other 1
Diagnostic Test 1
Dietary Supplement|placebo|Procedure 1
Other 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 35
NA 21
Japan 15
China 2
Spain 2
Thailand 2
United States|Puerto Rico 2
Australia 1
Austria 1
Belgium|Czechia|France|Germany|Greece|Hungary|Italy|Lithuania|Poland|Spain|United Kingdom 1
Brazil 1
China|Hong Kong|India|Korea, Republic of|Malaysia|Taiwan 1
China|Hong Kong|Korea, Republic of|Taiwan 1
Denmark 1
France 1
France|United States|Australia|Austria|Belgium|Canada|Czechia|Denmark|Germany|Greece|Hungary|Israel|Italy|Latvia|Lithuania|Netherlands|New Zealand|Poland|Portugal|Russian Federation|Spain|Sweden|Switzerland|Turkey 1
Germany 1
Germany|Poland 1
Hong Kong 1
Israel 1
Italy 1
Korea, Republic of 1
Malaysia 1
Mexico 1
Peru 1
United States|Argentina|India|Korea, Republic of|Malaysia|Russian Federation|Singapore|Taiwan|Turkey 1
United States|Australia 1
United States|Australia|Austria|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Russian Federation|Spain|Sweden|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Poland|Russian Federation|Spain|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Russian Federation|Spain|Sweden 1
United States|Austria|Belgium|Canada|Czechia|Denmark|Estonia|France|Germany|Greece|Hungary|Italy|Latvia|Lithuania|New Zealand|Poland|Portugal|Russian Federation|Spain|Sweden|Switzerland|Turkey 1
United States|Belgium|Czech Republic|Hungary|Italy|Macedonia, The Former Yugoslav Republic of|Poland|Portugal|Spain|Switzerland|Turkey|United Kingdom 1
United States|Belgium|Czechia|France|Germany|Greece|Hungary|Italy|Poland|Russian Federation|Ukraine 1
United States|Belgium|Germany|Lithuania|Poland|United Kingdom 1
United States|Canada 1
United States|Chile 1
United States|Czech Republic|Denmark|Germany|Greece|Italy|Netherlands|Portugal|Russian Federation|Spain|Sweden|United Kingdom 1
United States|Germany|United Kingdom 1

Sites per Study

Site_count Study_Count
1 62
2 5
3 2
4 1
5 2
6 5
7 1
8 2
10 2
11 1
12 5
13 2
14 2
15 1
16 1
18 1
19 1
33 1
34 2
36 1
40 1
45 1
55 1
83 1
90 1
106 1
118 1
183 1
209 1
229 1

Phase

Phase Study_Count
Phase 4 34
Phase 3 30
Phase 2 18
N/A 13
Phase 1 12
Phase 2/Phase 3 2
Phase 1/Phase 2 1

Number of Arms

Number_of_Arms Count_of_Studies
1 30
2 48
3 6
4 10
5 4
NA 12

Enrollment Metrics by Phase

Measure N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 18.00000 6.00000 20 35.0000 78 13.00 12.0000
1st Qu. 35.00000 13.75000 20 44.0000 217 63.00 41.0000
Median 48.00000 28.00000 20 61.5000 356 235.50 71.0000
Mean 86.61538 30.08333 20 128.1111 356 445.80 133.7576
3rd Qu. 69.00000 33.00000 20 109.2500 495 513.25 170.0000
Max. 502.00000 72.00000 20 850.0000 634 3883.00 750.0000

Trial Group Type

group_type Group_Count
Experimental 113
Active Comparator 57
Placebo Comparator 24
NA 12
Other 8
No Intervention 2

Intervention Model

intervention_model Study_Count
Parallel Assignment 63
Single Group Assignment 37
Crossover Assignment 7
Sequential Assignment 2
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 100
Basic Science 3
Diagnostic 2
Prevention 2
Other 1
Screening 1
Supportive Care 1

Observational Studies

Studies by Country

Country Study_Count
NA 4
Greece 3
Austria 2
Russian Federation 2
United States 2
Austria|Germany 1
Bulgaria|Czech Republic|Romania 1
France 1
Japan 1
Sweden 1
Turkey 1

Sites per Study

Site_count Study_Count
1 10
10 1
11 1
12 1
13 1
19 1
22 1
24 1
69 1
87 1

Enrollment Metrics

Measure Observational
Min 36.0000
1st Qu 71.7500
Median 247.0000
Mean 753.6111
3rd Qu 508.2500
Max 8020.0000

Observation Model

observational_model Study_Count
Cohort 9
NA 8
Case-Only 1
Defined Population, Natural History 1

Time Perspective

time_perspective Study_Count
Prospective 13
Retrospective 3
Cross-Sectional 1
Longitudinal, Prospective 1
NA 1

Registries

Studies by Country

Country Study_Count
Taiwan 1

Sites per Study

Site_count Study_Count
1 1

Enrollment Metrics

Measure Registries
Min 48
1st Qu 48
Median 48
Mean 48
3rd Qu 48
Max 48

Registry Model

observational_model Study_Count
Cohort 1

Time Perspective

time_perspective Study_Count
Prospective 1

Follow-up

target_duration Study_Count
4 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03960437 The Effect of Etelcalcetide on CKD-MBD https://ClinicalTrials.gov/show/NCT03960437 Recruiting Columbia University 2021-06-30
NCT03822507 Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia https://ClinicalTrials.gov/show/NCT03822507 Recruiting Kyowa Kirin Co., Ltd. 2021-03-31
NCT03299244 Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian HD Subjects With SHPT https://ClinicalTrials.gov/show/NCT03299244 Completed Amgen 2020-04-08
NCT03283098 A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416 https://ClinicalTrials.gov/show/NCT03283098 Completed Amgen 2019-02-04
NCT03226171 Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT03226171 Completed Sanwa Kagaku Kenkyusho Co., Ltd. 2018-09-11
NCT03182699 Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients https://ClinicalTrials.gov/show/NCT03182699 Completed Medical University of Vienna 2019-12-20
NCT03123406 Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT https://ClinicalTrials.gov/show/NCT03123406 Completed Kyowa Hakko Kirin China Pharmaceutical Co., LTD. 2019-04-20
NCT02895061 Effectiveness of Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients. https://ClinicalTrials.gov/show/NCT02895061 Completed Phramongkutklao College of Medicine and Hospital 2015-10-31
NCT02859896 Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis https://ClinicalTrials.gov/show/NCT02859896 Recruiting Sanofi 2022-04-05
NCT02830789 Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass https://ClinicalTrials.gov/show/NCT02830789 Completed University of Aarhus 2017-05-31
NCT02341417 Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis https://ClinicalTrials.gov/show/NCT02341417 Completed Amgen 2017-03-15
NCT02549417 Phase 3 Study of KHK7580 https://ClinicalTrials.gov/show/NCT02549417 Completed Kyowa Kirin Co., Ltd. 2016-12-22
NCT02549404 Phase 3 Study of KHK7580 https://ClinicalTrials.gov/show/NCT02549404 Completed Kyowa Kirin Co., Ltd. 2016-12-06
NCT02549391 Phase 3 Study of KHK7580 https://ClinicalTrials.gov/show/NCT02549391 Completed Kyowa Kirin Co., Ltd. 2016-11-30
NCT02524041 Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT02524041 Completed Centre Hospitalier Universitaire de Saint Etienne 2016-04-30
NCT02464072 Subtotal Parathyroidectomy or Total Parathyroidectomy With Autograft in Chronic Kidney Disease Patients Under Dialysis https://ClinicalTrials.gov/show/NCT02464072 Active, not recruiting University of Sao Paulo General Hospital 2021-03-31
NCT02282813 Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 https://ClinicalTrials.gov/show/NCT02282813 Completed OPKO Health, Inc. 2015-05-31
NCT02274623 Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid https://ClinicalTrials.gov/show/NCT02274623 Completed OPKO Health, Inc. 2017-02-27
NCT02216656 Phase 2 Study of KHK7580 https://ClinicalTrials.gov/show/NCT02216656 Completed Kyowa Kirin Co., Ltd. 2015-02-28
NCT02143271 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis https://ClinicalTrials.gov/show/NCT02143271 Completed Kyowa Kirin Co., Ltd. 2014-12-31
NCT02133404 A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis https://ClinicalTrials.gov/show/NCT02133404 Completed Astellas Pharma Inc 2014-11-10
NCT02102204 Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis https://ClinicalTrials.gov/show/NCT02102204 Completed Amgen 2016-11-04
NCT01290029 Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease https://ClinicalTrials.gov/show/NCT01290029 Completed Amgen 2015-09-23
NCT02056730 The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid https://ClinicalTrials.gov/show/NCT02056730 Completed Chulalongkorn University 2015-02-28
NCT02054572 Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis https://ClinicalTrials.gov/show/NCT02054572 Completed Amgen 2014-04-15
NCT01939977 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. https://ClinicalTrials.gov/show/NCT01939977 Completed Fundación Senefro 2015-09-30
NCT01935856 Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis https://ClinicalTrials.gov/show/NCT01935856 Completed Kyowa Kirin Co., Ltd. 2014-03-31
NCT01932970 Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide https://ClinicalTrials.gov/show/NCT01932970 Completed Amgen 2014-01-14
NCT01922843 A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis https://ClinicalTrials.gov/show/NCT01922843 Completed Deltanoid Pharmaceuticals 2014-05-31
NCT01896232 Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet https://ClinicalTrials.gov/show/NCT01896232 Completed Amgen 2014-11-12
NCT01788046 Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis https://ClinicalTrials.gov/show/NCT01788046 Completed Amgen 2014-04-14
NCT01785875 Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis https://ClinicalTrials.gov/show/NCT01785875 Completed Amgen 2015-07-01
NCT01785849 Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis https://ClinicalTrials.gov/show/NCT01785849 Completed Amgen 2014-05-22
NCT01704079 Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency https://ClinicalTrials.gov/show/NCT01704079 Completed OPKO Health, Inc. 2014-08-31
NCT01653379 A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT01653379 Completed Deltanoid Pharmaceuticals 2014-07-31
NCT01651000 Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency https://ClinicalTrials.gov/show/NCT01651000 Completed OPKO Health, Inc. 2014-07-31
NCT01506947 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients https://ClinicalTrials.gov/show/NCT01506947 Completed AbbVie 2016-04-07
NCT01414114 Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder https://ClinicalTrials.gov/show/NCT01414114 Completed KAI Pharmaceuticals 2012-05-21
NCT01382212 A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis https://ClinicalTrials.gov/show/NCT01382212 Completed AbbVie 2015-04-30
NCT01341782 Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT01341782 Completed AbbVie 2012-04-30
NCT04064827 A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) https://ClinicalTrials.gov/show/NCT04064827 Recruiting AbbVie 2024-03-09
NCT03969329 A Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis https://ClinicalTrials.gov/show/NCT03969329 Recruiting Amgen 2022-06-29
NCT03801980 Phase 3 Study of SK-1403 https://ClinicalTrials.gov/show/NCT03801980 Completed Sanwa Kagaku Kenkyusho Co., Ltd. 2019-12-17
NCT03633708 Study of Etelcalceide in Pediatric Subjects With Secondary Hyperparathyroidism and CKD on Hemodialysis https://ClinicalTrials.gov/show/NCT03633708 Recruiting Amgen 2023-01-31
NCT03626948 SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis https://ClinicalTrials.gov/show/NCT03626948 Completed Sanwa Kagaku Kenkyusho Co., Ltd. 2020-02-04
NCT03602261 Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI https://ClinicalTrials.gov/show/NCT03602261 Recruiting OPKO Health, Inc. 2020-12-31
NCT03588884 Repeated-dose Safety, Efficacy, PK and PD of CTAP101, IR Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With SHPT, CKD 3-4 and VDI https://ClinicalTrials.gov/show/NCT03588884 Recruiting OPKO Health, Inc. 2020-03-17
NCT01254565 Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT01254565 Completed KAI Pharmaceuticals 2011-07-31
NCT01220050 Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT01220050 Completed Mario Negri Institute for Pharmacological Research 2012-07-31
NCT01219855 Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) https://ClinicalTrials.gov/show/NCT01219855 Completed OPKO Health, Inc. 2011-11-30
NCT01191762 Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease https://ClinicalTrials.gov/show/NCT01191762 Completed Phelps, Kenneth R., M.D. 2012-08-31
NCT01181531 Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis https://ClinicalTrials.gov/show/NCT01181531 Completed Amgen 2012-07-17
NCT01178450 Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation https://ClinicalTrials.gov/show/NCT01178450 Completed Hospital Universitari de Bellvitge 2014-09-30
NCT01167309 LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients https://ClinicalTrials.gov/show/NCT01167309 Completed LEO Pharma 2011-10-31
NCT01143987 Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT01143987 Completed Chinese University of Hong Kong 2013-02-28
NCT01138475 Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery https://ClinicalTrials.gov/show/NCT01138475 Completed William Beaumont Hospitals 2015-08-31
NCT01134562 Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT01134562 Completed KAI Pharmaceuticals 2011-04-02
NCT01134549 Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers https://ClinicalTrials.gov/show/NCT01134549 Completed KAI Pharmaceuticals 2010-07-31
NCT01115543 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT01115543 Completed Mahidol University 2009-08-31
NCT01101113 Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level https://ClinicalTrials.gov/show/NCT01101113 Completed Seoul National University Hospital 2012-03-31
NCT01100723 Trial to Optimize Mineral Outcomes in Dialysis Patients https://ClinicalTrials.gov/show/NCT01100723 Completed University of Colorado, Denver 2011-08-31
NCT01025128 Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density https://ClinicalTrials.gov/show/NCT01025128 Completed Clalit Health Services 2014-07-31
NCT00999037 FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease https://ClinicalTrials.gov/show/NCT00999037 Completed University of California, Los Angeles 2015-06-30
NCT00990704 Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT00990704 Completed Abbott 2010-05-31
NCT00977080 Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D https://ClinicalTrials.gov/show/NCT00977080 Completed Abbott 2011-05-31
NCT00958451 Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients https://ClinicalTrials.gov/show/NCT00958451 Completed Salem Veterans Affairs Medical Center 2011-01-31
NCT00891813 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose https://ClinicalTrials.gov/show/NCT00891813 Completed Abbott 2010-09-30
NCT00888069 Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects https://ClinicalTrials.gov/show/NCT00888069 Completed OPKO Health, Inc. 2009-11-30
NCT03660800 Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects https://ClinicalTrials.gov/show/NCT03660800 Completed OPKO Health, Inc. 2018-10-24
NCT02833857 A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis https://ClinicalTrials.gov/show/NCT02833857 Completed Amgen 2018-10-31
NCT00828347 Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT) https://ClinicalTrials.gov/show/NCT00828347 Completed Kumamoto University 2009-07-31
NCT00823303 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) https://ClinicalTrials.gov/show/NCT00823303 Completed Washington University School of Medicine 2013-05-31
NCT00803712 20070360 Incident Dialysis https://ClinicalTrials.gov/show/NCT00803712 Completed Amgen 2010-12-09
NCT00792857 Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT) https://ClinicalTrials.gov/show/NCT00792857 Completed OPKO Health, Inc. 2009-09-30
NCT00781417 Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease https://ClinicalTrials.gov/show/NCT00781417 Completed Atlanta VA Medical Center 2011-10-31
NCT00754442 Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT00754442 Completed University of Maryland, Baltimore 2008-08-31
NCT00742716 Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease https://ClinicalTrials.gov/show/NCT00742716 Completed OPKO Health, Inc. 2010-02-28
NCT00701805 Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD) https://ClinicalTrials.gov/show/NCT00701805 Completed Abbott 2009-12-31
NCT00667576 Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis https://ClinicalTrials.gov/show/NCT00667576 Completed Abbott 2009-03-31
NCT00800358 Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT00800358 Completed Penang Hospital, Malaysia 2009-10-31
NCT00601328 Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions https://ClinicalTrials.gov/show/NCT00601328 Completed West-Ward Pharmaceutical 2003-08-31
NCT00587158 Oral Paricalcitol in Kidney Transplant Recipients https://ClinicalTrials.gov/show/NCT00587158 Completed Mayo Clinic 2011-11-30
NCT00560300 Regulation of Bone Formation in Renal Osteodystrophy https://ClinicalTrials.gov/show/NCT00560300 Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NA
NCT00537979 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis https://ClinicalTrials.gov/show/NCT00537979 Completed Abbott 2010-07-31
NCT00528788 How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis https://ClinicalTrials.gov/show/NCT00528788 Completed Duke University 2012-08-31
NCT00463021 A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection https://ClinicalTrials.gov/show/NCT00463021 Completed Sanofi NA
NCT00454350 A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis https://ClinicalTrials.gov/show/NCT00454350 Completed Sanofi NA
NCT00431496 A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) https://ClinicalTrials.gov/show/NCT00431496 Completed Amgen 2009-06-30
NCT00418600 A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis https://ClinicalTrials.gov/show/NCT00418600 Completed Sanofi 2007-06-30
NCT00397475 Evaluation of Colecalciferol Substitution in Dialysis Patients https://ClinicalTrials.gov/show/NCT00397475 Completed University Hospital, Saarland NA
NCT00379899 ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis https://ClinicalTrials.gov/show/NCT00379899 Completed Amgen 2009-05-31
NCT00352170 Calcium and Vitamin D Malnutrition in Elderly Women https://ClinicalTrials.gov/show/NCT00352170 Completed Creighton University 2005-07-31
NCT00345839 E.V.O.L.V.E. Trialâ„¢: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events https://ClinicalTrials.gov/show/NCT00345839 Completed Amgen 2012-04-10
NCT00307840 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT00307840 Completed Papageorgiou General Hospital NA
NCT00288873 Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity https://ClinicalTrials.gov/show/NCT00288873 Completed Weill Medical College of Cornell University 2007-07-31
NCT00285467 Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease https://ClinicalTrials.gov/show/NCT00285467 Completed Indiana University 2009-12-31
NCT00261950 Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease https://ClinicalTrials.gov/show/NCT00261950 Completed Amgen 2011-05-31
NCT00257920 A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease https://ClinicalTrials.gov/show/NCT00257920 Completed Abbott 2008-01-31
NCT00211939 CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients https://ClinicalTrials.gov/show/NCT00211939 Completed Nabi Biopharmaceuticals 2006-12-31
NCT00135304 ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT00135304 Completed Amgen 2006-10-31
NCT00132431 START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT00132431 Completed Amgen NA
NCT00123461 Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT00123461 Completed Sanofi 2007-10-31
NCT00117052 SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT00117052 Completed Amgen 2005-11-30
NCT00110929 Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD) https://ClinicalTrials.gov/show/NCT00110929 Completed Amgen NA
NCT00094484 Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis https://ClinicalTrials.gov/show/NCT00094484 Completed Amgen NA
NCT00073710 Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium https://ClinicalTrials.gov/show/NCT00073710 Completed Abbott NA
NCT00053547 Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis https://ClinicalTrials.gov/show/NCT00053547 Completed Abbott NA
NCT00042653 A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis https://ClinicalTrials.gov/show/NCT00042653 Completed Amgen 2003-07-31
NCT00042432 Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients https://ClinicalTrials.gov/show/NCT00042432 Completed Amgen 2003-03-31
NCT00037635 A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients https://ClinicalTrials.gov/show/NCT00037635 Completed Amgen 2003-03-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03137316 Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy https://ClinicalTrials.gov/show/NCT03137316 Completed Benha University 2017-02-28
NCT02523209 Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation https://ClinicalTrials.gov/show/NCT02523209 Completed Centre Hospitalier Universitaire de Saint Etienne 2017-04-30
NCT01741064 Morbidity Related to Secondary Hyperparathyroidism After Renal Transplantation https://ClinicalTrials.gov/show/NCT01741064 Completed Skane University Hospital 2012-10-31
NCT01401478 Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation https://ClinicalTrials.gov/show/NCT01401478 Completed AbbVie 2013-01-31
NCT01368042 Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous https://ClinicalTrials.gov/show/NCT01368042 Completed AbbVie 2013-06-30
NCT03937349 Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients https://ClinicalTrials.gov/show/NCT03937349 Recruiting Saint Petersburg State University, Russia 2020-12-31
NCT03626246 Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease https://ClinicalTrials.gov/show/NCT03626246 Recruiting Columbia University 2020-01-01
NCT03464149 The Longitudinal PTH-Study https://ClinicalTrials.gov/show/NCT03464149 Completed Medical University of Vienna 2018-12-05
NCT01265992 Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis https://ClinicalTrials.gov/show/NCT01265992 Completed AbbVie 2012-11-30
NCT01224782 Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT) https://ClinicalTrials.gov/show/NCT01224782 Completed AbbVie 2013-08-31
NCT01149291 A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator’s for Prevention and Treatment of Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT01149291 Completed AbbVie 2014-12-31
NCT01083849 Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice https://ClinicalTrials.gov/show/NCT01083849 Completed AbbVie 2013-12-31
NCT01083186 Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience https://ClinicalTrials.gov/show/NCT01083186 Completed AbbVie 2012-01-31
NCT01081665 Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism https://ClinicalTrials.gov/show/NCT01081665 Completed Abbott 2011-02-28
NCT01073462 Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years https://ClinicalTrials.gov/show/NCT01073462 Completed AbbVie 2013-06-30
NCT00995163 Mineral and Bone Disorders Outcomes in Stage 5D of Chronic Kidney Disease https://ClinicalTrials.gov/show/NCT00995163 Completed Kyowa Kirin Co., Ltd. 2011-01-31
NCT00395902 Post Transplant Study https://ClinicalTrials.gov/show/NCT00395902 Completed Amgen NA
NCT00189501 A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD) https://ClinicalTrials.gov/show/NCT00189501 Completed Amgen NA
NCT00037193 Acute Regulation of Parathyroid Hormone by Dietary Phosphate https://ClinicalTrials.gov/show/NCT00037193 Completed National Center for Research Resources (NCRR) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT04267965 Pulmonary Function, Voice and Swallowing Symptoms After Parathyroidectomy https://ClinicalTrials.gov/show/NCT04267965 Completed Chang Gung Memorial Hospital 2019-07-31